What are the specific side effects of lurbinectedin?

How often do patients experience low blood cell counts with lurbinectedin?
Low blood cell counts are the most common effects reported in clinical use. Neutropenia occurs in roughly 80 % of patients, and about 40 % develop severe (grade 3–4) neutropenia. Anemia and thrombocytopenia appear in 60–70 % of cases, though fewer reach grade 3–4 levels. Dose reductions or delays are required in up to 30 % of patients because of these drops.

What gastrointestinal problems does lurbinectedin cause?
Nausea, vomiting, constipation, and diarrhea are frequent. Nausea affects about half of patients; anti-emetics are routinely given before each infusion. Constipation and diarrhea are milder and usually improve with supportive care.

Can lurbinectedin affect the liver or kidneys?
Liver-enzyme elevations (ALT/AST) are seen in up to 40 % of patients, most often grade 1–2. Kidney-function changes are uncommon, but creatinine increases have been noted in a small percentage of cases; monitoring every cycle is recommended.

Are there other side effects patients should watch for?
Fatigue is reported in roughly 50 % of patients. Muscle or joint pain, decreased appetite, and hair loss occur in 10–20 %. Rare but serious effects include interstitial lung disease and infusion reactions; both warrant immediate medical attention if breathing difficulty or rash develops.

How do side-effect rates compare with topotecan?
In head-to-head data, lurbinectedin produced lower rates of severe neutropenia and anemia than topotecan, but similar rates of nausea and fatigue. Fewer patients on lurbinectedin needed transfusions or growth-factor support.

When do side effects usually appear and how long do they last?
Blood-count nadirs occur 7–14 days after each dose, with recovery by day 21 in most patients. Gastrointestinal effects peak within 24–48 hours of infusion and generally resolve within a week. Liver-enzyme rises tend to be transient and return to baseline before the next cycle.

Do side effects change when lurbinectedin is combined with other drugs?
Combination regimens increase the frequency and severity of neutropenia and fatigue. Dose adjustments of lurbinectedin and the partner agent are common. Ongoing trials are testing lower starting doses to improve tolerability.

What support measures reduce the impact of side effects?
Primary prophylaxis with G-CSF is used in many centers when baseline counts are low. Aggressive anti-emetic regimens, stool softeners, and hydration help control nausea and constipation. Weekly blood-count checks allow early dose holds or reductions before complications arise.

[1] https://www.drugpatentwatch.com/drug/lurbinectedin
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf